Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc. stock (symbol: BNTC) underwent a total of 5 stock splits.
The most recent stock split occured on Jul 26, 2023.
Date | Splite | Multiple |
---|---|---|
2023-07-26 | 1:17 | 1 |
2020-04-15 | 2:3 | 2 |
2019-11-18 | 1:10 | 1 |
2018-05-02 | 1019:1000 | 1019 |
2015-06-16 | 1:4 | 1 |